siRNA-mediated silencing of notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 6, 2012, Pages 2485-2489

  Ye, Qi Fa ^a   Zhang, Yi Chuan ^a,b   Peng, Xiao Qing ^b   Long, Zhi ^b   Ming, Ying Zi ^a   He, Le Ye ^a,b  

^a Medicine of the National Ministry of Health   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Akt; Apoptosis; Cell cycle; Notch signaling; Prostate cancer; siRNA

Indexed keywords

EID: 84872190576     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.6.2485     Document Type: Article

References (28)

1. Ando T, Kawabe T, Ohara H, et al. (2001). Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem, 276, 42971-7.
2. Artavanis-Tsakonas S, Rand MD, Lake RJ, (1999). Notch signaling: cell fate control and signal integration in development. Science, 284, 770-6.
3. Brazil DP, Hemmings BA, (2001). Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci, 26, 657-64.
4. Deng C, Zhang P, Harper JW, et al. (1995). Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82, 675-84.
5. De Siervi A, Marinissen M, Diggs J, et al. (2004). Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1. Cancer Res, 64, 743-50.
6. el-Deiry WS, Tokino T, Velculescu VE, et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-25.
7. Kopan R, Ilagan MX, (2009). The canonical Notch signaling pathway: unfolding the activation mechanism. Cell, 137, 216-33.
8. Livak KJ, Schmittgen TD, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8.
9. Li Z, Wang J, Gong L, et al. (2011). Correlation of Delta-like ligand 4 (DLL4) with VEGF and HIF-1alpha expression in human glioma. Asian Pac J Cancer Prev, 12, 215-8.
10. McGrogan BT, Gilmartin B, Camey DN, McCann A. (2008). Taxanes, microtubules and chemoresistant breast cancer. Bba Rev Cancer, 1785, 96-132.
11. Miele L. (2006). Notch signaling. Clin Cancer Res, 12, 1074-79
12. Miele L, Golde T, Osborne B. (2006). Notch signaling in cancer. Curr Mol Med, 6, 905-18.
13. Mungamuri SK, Yang YH, Thor AD, Somasundaram K, (2006). Survival signaling by Notch1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res, 66, 4715-24.
14. Nefedova Y, Sullivan DM, Bolick SC, et al. (2008). Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood, 111, 2220-29.
15. Petrylak DP, Tangen CM, Hussain MHA, et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med, 351, 1513-20.
16. Ranganathan P, Weaver KL, Capobianco AJ, (2011). Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer, 11, 338-51.
17. Reagan-Shaw S, Nihal M, Ahsan H, et al. (2008). Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Prostate, 68, 1624-34.
18. Reed SI, (2002). Keeping p27(Kip1) in the cytoplasm: a second front in cancers war on p27. Cell Cycle, 1, 389-90.
19. Rigberg DA, Blinman TA, Kim FS, et al. (1999). Antisense blockade of p21/WAF1 decreases radiation-induced G2 arrest in esophageal squamous cell carcinoma. J Surg Res, 81, 6-10.
20. Ronchini C, Capobianco AJ, (2001). Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): Implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol, 21, 5925-34.
21. Sade H, Krishna S, Sarin A, (2004). The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem, 279, 2937-44.
22. Seruga B, Ocana A, Tannock IF, (2011). Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol, 8, 12-23.
23. Stylianou S, Clarke RB, Brennan K, (2006). Aberrant activation of Notch signaling in human breast cancer. Cancer Res, 66, 1517-25.
24. Tannock IF, de Wit R, Berry WR, et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med, 351, 1502-12.
25. Villaronga MA, Bevan CL, Belandia B, (2008). Notch Signaling: A Potential Therapeutic Target in Prostate Cancer. Curr Cancer Drug Tar, 8, 566-80.
26. Wang ZW, Li YW, Ahmad A, et al. (2011). Down-Regulation of Notch-1 Is Associated With Akt and FoxM1 in Inducing Cell Growth Inhibition and Apoptosis in Prostate Cancer Cells. J Cell Biochem, 112, 78-88.
27. Zhang F, Chen A, Chen J, et al. (2011). SiRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells. Asian Pac J Cancer Prev, 12, 239-45.
28. Zhang YX, Wang ZW, Ahmed F, et al. (2006). Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer, 119, 2071-7.